Clinical and Haemodynamic Study of Atenolol (Tenormin) in Essential Hypertension
Keyword(s):
1. The β1-adrenoreceptor-blocking agent atenolol was studied in the treatment of twelve out-patients with essential hypertension. 2. With a mean dose of 110 mg of atenolol daily (range 75–200 mg/day) we observed a pronounced decrease in blood pressure. 3. Only minimal side effects were seen. 4. Cardiac output decreased from 4·6 to 3·4 l/min during treatment. This decrease did not correlate with the decrease in blood pressure but correlated well with the changes in calculated total peripheral resistance.
1986 ◽
Vol 14
(03n04)
◽
pp. 153-156
◽
1988 ◽
Vol 254
(4)
◽
pp. H811-H815
◽
1989 ◽
Vol 256
(3)
◽
pp. R778-R785
◽
1991 ◽
Vol 260
(1)
◽
pp. H254-H259
2001 ◽
Vol 281
(6)
◽
pp. H2511-H2517
◽
1983 ◽
Vol 61
(2)
◽
pp. 149-153
◽
1956 ◽
Vol 186
(1)
◽
pp. 101-104
◽